Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 9/20 | 0.46 |
| ▸ | RXRA | P19793 | 8/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IP6K1 | Q92551 | 8/20 | 0.44 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.44 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30623443 | 1.00 | NR1H2 (0.46) | NR1H2RXRANR1H3MEN1KMT2A | |
| SCHEMBL23648571 | 0.84 | IP6K1 (0.55) | MEN1KMT2AIP6K1IP6K3IP6K2 | |
| SCHEMBL3725089 | 0.82 | IP6K1 (0.51) | NR1H2RXRANR1H3MEN1KMT2A | |
| SCHEMBL24454023 | 0.82 | IP6K1 (0.40) | NR1H2RXRANR1H3MEN1KMT2A | |
| SCHEMBL24451644 | 0.82 | IP6K1 (0.40) | NR1H2RXRANR1H3MEN1KMT2A | |
| SCHEMBL24451648 | 0.79 | IMPDH2 (0.40) | NR1H2RXRANR1H3MEN1KMT2A | |
| SCHEMBL24454022 | 0.79 | IMPDH2 (0.40) | NR1H2RXRANR1H3MEN1KMT2A | |
| SCHEMBL26007667 | 0.79 | MEN1 (0.43) | MEN1KMT2AIP6K1IP6K3IP6K2 | |
| SCHEMBL30623350 | 0.78 | ALDH1A1 (0.38) | NR1H2RXRANR1H3MEN1KMT2A | |
| SCHEMBL26016812 | 0.78 | ALDH1A1 (0.38) | NR1H2RXRANR1H3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195483-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195483-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, SAAL1 | NR1H2 88/4885RXRA 4210/4885NR1H3 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.